More importantly, a subgroup analysis reveals that if the serum IGF-1 levels are within the target therapeutic range, there is an extreme 89% decrease in the rate of severe BPD, 4.8% vs. 44.9%. Here, IGF1 is linked to bronchopulmonary dysplasia.